WO1996026961A3 - Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use - Google Patents

Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use Download PDF

Info

Publication number
WO1996026961A3
WO1996026961A3 PCT/US1996/002289 US9602289W WO9626961A3 WO 1996026961 A3 WO1996026961 A3 WO 1996026961A3 US 9602289 W US9602289 W US 9602289W WO 9626961 A3 WO9626961 A3 WO 9626961A3
Authority
WO
WIPO (PCT)
Prior art keywords
itim
reagents
present
regulating
hematopoietic function
Prior art date
Application number
PCT/US1996/002289
Other languages
French (fr)
Other versions
WO1996026961A2 (en
Inventor
John C Cambier
Original Assignee
Nat Jewish Ct Immun & Respirat
John C Cambier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Ct Immun & Respirat, John C Cambier filed Critical Nat Jewish Ct Immun & Respirat
Priority to AU52967/96A priority Critical patent/AU5296796A/en
Priority to EP96909494A priority patent/EP0812330A2/en
Priority to JP8526316A priority patent/JPH11501622A/en
Publication of WO1996026961A2 publication Critical patent/WO1996026961A2/en
Publication of WO1996026961A3 publication Critical patent/WO1996026961A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention is directed to a novel product and method for regulating hematopoietic cell function and a novel product and method for identifying compounds capable of regulating inflammation. The present invention includes a method to regulate hematopoietic cell function by contacting a cell with a regulatory reagent capable of altering the activity of a molecule including PTP1C, PTP1D, ITIM-p160 and ITIM-p70. The present invention also relates regulatory reagents capable of regulating the activity of PTP1C, PTP1D, ITIM-p160 and ITIM-p70, including nucleic acid molecules having sequences that encode such reagents and antibodies raised against such reagents. The present invention also includes a therapeutic composition comprising such reagents and their use to protect animals from inflammation.
PCT/US1996/002289 1995-02-28 1996-02-28 Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use WO1996026961A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU52967/96A AU5296796A (en) 1995-02-28 1996-02-28 Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
EP96909494A EP0812330A2 (en) 1995-02-28 1996-02-28 Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
JP8526316A JPH11501622A (en) 1995-02-28 1996-02-28 Peptidyl compounds containing ITIM motif that regulate hematopoietic function and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39762895A 1995-02-28 1995-02-28
US08/397,628 1995-02-28

Publications (2)

Publication Number Publication Date
WO1996026961A2 WO1996026961A2 (en) 1996-09-06
WO1996026961A3 true WO1996026961A3 (en) 1997-04-10

Family

ID=23571989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002289 WO1996026961A2 (en) 1995-02-28 1996-02-28 Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use

Country Status (5)

Country Link
EP (1) EP0812330A2 (en)
JP (1) JPH11501622A (en)
AU (1) AU5296796A (en)
CA (1) CA2247207A1 (en)
WO (1) WO1996026961A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804218A1 (en) * 1994-03-17 1997-11-05 National Jewish Center For Immunology And Respiratory Medicine Product and process for regulating signal transduction pathways
EP0861891A1 (en) * 1996-12-31 1998-09-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for modulating cell negative regulations and biological applications thereof
AU8661498A (en) * 1997-08-01 1999-02-22 Schering Corporation Mammalian cell membrane proteins; related reagents
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
FR2783325A1 (en) * 1998-09-11 2000-03-17 Inst Nat Sante Rech Med Screening assay for inhibitors of tyrosine kinase receptor activation comprises detecting compounds that induce co-aggregation with immunoreceptor tyrosine-based inhibition motif receptors
US6355786B1 (en) 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
JP2002537357A (en) * 1999-02-25 2002-11-05 ナショナル ジューイッシュ メディカル アンド リサーチ センター Products and methods for treating conditions associated with receptor desensitization
AU2001247543A1 (en) * 2001-03-16 2003-09-02 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy of allergies
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2007122815A1 (en) * 2006-04-14 2007-11-01 Ono Pharmaceutical Co., Ltd. Bivalent antibody directed against bir1
KR101258456B1 (en) 2011-01-13 2013-04-26 강원대학교산학협력단 Pharmaceutical composition comprising peptide having inhibitory activities against transendothelial migration of leucocytes and degranulation of mast cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304279A2 (en) * 1987-08-17 1989-02-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide determinant associated with immunity
EP0432691A1 (en) * 1989-12-10 1991-06-19 Yeda Research And Development Company Limited An assay for direct binding of peptides that are T-cell epitopes to MHC gene products on intact antigen-presenting cells and the use thereof for screening susceptibility to autoimmune diseases
WO1994025570A1 (en) * 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304279A2 (en) * 1987-08-17 1989-02-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide determinant associated with immunity
EP0432691A1 (en) * 1989-12-10 1991-06-19 Yeda Research And Development Company Limited An assay for direct binding of peptides that are T-cell epitopes to MHC gene products on intact antigen-presenting cells and the use thereof for screening susceptibility to autoimmune diseases
WO1994025570A1 (en) * 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents

Also Published As

Publication number Publication date
EP0812330A2 (en) 1997-12-17
CA2247207A1 (en) 1996-09-06
WO1996026961A2 (en) 1996-09-06
AU5296796A (en) 1996-09-18
JPH11501622A (en) 1999-02-09

Similar Documents

Publication Publication Date Title
WO1996026961A3 (en) Peptidyl compounds comprising an itim motif which regulate hematopoietic function and their use
PT990047E (en) METHODS AND COMPOSITIONS FOR THE ANALYSIS OF NUCLEIC ACIDS BY MASS SPECTROSCOPY.
AU7433891A (en) Electrochemiluminescent assays
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
FR2703052B1 (en) New method of nucleic acid sequencing.
ES2156978T3 (en) USE OF EXONUCLEASE AND / OR GLYCOSYLASE AS SUPPLEMENTS OF AN ANTIPOLIMERASE ANTIBODY TO INCREASE SPECIFITY IN THE POLYMERASE CHAIN REACTION.
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
IE822628L (en) Fenclofenac as tbp blocking agent in iodothyroneine¹immunoassays
AU6975694A (en) Salmonella identification by the polymerase chain reaction
EP1449849A3 (en) Protease-resistant thrombomodulin analog
FI902934A0 (en) FOERFARANDE FOER BESTAEMNING AV NUCLEINSYRA.
Blumberg et al. Reversible inactivation and superactivation by covalent modification of thermolysin
WO2001016170A3 (en) Card proteins involved in cell death regulation
Subramani et al. Ligand-promoted weakening of intersubunit bonding domains in aspartate transcarbamoylase
Kessler et al. The two effects of rifampicin on the RNA polymerase reaction
AU532401B2 (en) Penam-3-alpha-carboxylic acid 1,1-dioxides
DE69010956D1 (en) Process for the synthesis of silicon compounds containing acylamino groups.
Sprinzl et al. Role of the 5′-terminal phosphate of tRNA for its function during protein biosynthesis elongation cycle
Scholz et al. Brain pyridoxal kinase: photoaffinity labeling of the substrate-binding site
Hasegawa et al. In vivo and in vitro effects of methylmercury on the activities of aminoacyl-tRNA synthetases in rat brain
Rosenblat et al. Inhibition of bacterial urease by autoxidation of furan C-18 fatty acid methyl ester products
DD158109A1 (en) METHOD FOR INHIBITING THE CATALYTIC ACTIVITY OF PEPTIDE HYDROLASES
DE59809481D1 (en) Process for the preparation of aminocyanacetamide
HUT38206A (en) Herbicides containing as reagent derivatives of cyclohexan-1,3-dion and process for production of the reagents
DE69627121D1 (en) CHEMICAL MODIFICATION OF PARTICULATE REAGENTS BY THEIR SYNTHESIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 526316

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996909494

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996909494

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2247207

Country of ref document: CA

Ref country code: CA

Ref document number: 2247207

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1996909494

Country of ref document: EP